Accentia Company Description
Accentia Biopharmaceuticals emphasizes runny noses. The company acquires and develops treatments for respiratory conditions, as well as other ailments. Accentia has several pharmaceutical products on the market, including Respi-TANN and Zinotic. Its development-stage drugs include sinus inflammation treatment SinuNase, multiple sclerosis drug Revimmune, and BiovaxID, a possible vaccine for non-Hodgkin's lymphoma being developed by majority owned subsidiary Biovest International. Accentia also develops cell production instruments, including the AutovaxID system, and offers pharmaceutical product consulting services.
View the Comprehensive Company Description for Accentia
The Company Description provides a historical perspective of Accentia's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Accentia's evolution in the marketplace.
